Organism ID | Organism Name | Taxonomy Level | Family | SuperKingdom | Isolation Part | Collection Location | Collection Time | Reference |
---|---|---|---|---|---|---|---|---|
NPO1797 | Homo sapiens | Species | Hominidae | Eukaryota | saliva |
PMID[23857558] |
||
NPO20338 | Mus musculus | Species | Muridae | Eukaryota |
PMID[19425150] |
|||
NPO730 | Escherichia coli | Species | Enterobacteriaceae | Bacteria |
PMID[21988831] |
Target ID | Target Type | Target Name | Target Organism | Activity Type | Activity Relation | Value | Unit | Reference |
---|---|---|---|---|---|---|---|---|
NPT5288 | Individual Protein | CMP-N-acetylneuraminate-beta-1,4-galactoside alpha-2,3-sialyltransferase | Rattus norvegicus | Ki | = | 65000 | nM | 12482445 |
NPT5289 | Individual Protein | CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,6-sialyltransferase | Rattus norvegicus | Ki | = | 64000 | nM | 12482445 |
NPT137 | Cell Line | L1210 | Mus musculus | ID50 | = | 0.35 | nM | 7057424 |
NPT319 | Cell Line | B16 | Mus musculus | ID50 | = | 1.5 | nM | 7057424 |
NPT137 | Cell Line | L1210 | Mus musculus | IC50 | = | 430 | nM | 1906107 |
NPT137 | Cell Line | L1210 | Mus musculus | IC50 | = | 410 | nM | 1906107 |
NPT2 | Others | Unspecified | Ratio | = | 0.95 | 1906107 | ||
NPT2 | Others | Unspecified | IC50 | > | 100000 | nM | 8709123 | |
NPT2 | Others | Unspecified | IC50 | = | 10000 | nM | 8709123 | |
NPT404 | Cell Line | CCRF-CEM | Homo sapiens | IC50 | = | 100 | nM | 8917645 |
NPT137 | Cell Line | L1210 | Mus musculus | ED50 | = | 0.05 | nM | 3968680 |
NPT137 | Cell Line | L1210 | Mus musculus | ID50 | = | 43 | ug/ml | 2535876 |
NPT2 | Others | Unspecified | Kd | = | 903630 | nM | 19320487 | |
NPT909 | Individual Protein | Seminal ribonuclease | Bos taurus | Ki | = | 1557900 | nM | 19643512 |
NPT908 | Individual Protein | Ribonuclease pancreatic | Bos taurus | Ki | = | 844200 | nM | 19643512 |
NPT1393 | Individual Protein | Orotidine phosphate decarboxylase | Plasmodium falciparum | Ki | > | 10000000 | nM | 22991951 |
NPT1394 | Individual Protein | Uridine 5'-monophosphate synthase | Homo sapiens | Ki | = | 1400000 | nM | 22991951 |
NPT1395 | Individual Protein | Orotidine 5'-phosphate decarboxylase | Methanobacterium thermoautotrophicum | Ki | = | 1200000 | nM | 22991951 |
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules. Tc lies between [0, 1] where '1' indicates the highest similarity. What is Tanimoto coefficient
●  The left chart: Distribution of similarity level between NPC226769 and all remaining natural products in the NPASS database.
●  The right table: Most similar natural products (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Natural Product ID |
---|---|---|
1.0 | High Similarity | NPC6166 |
1.0 | High Similarity | NPC280946 |
0.9886 | High Similarity | NPC120887 |
0.9775 | High Similarity | NPC328779 |
0.9663 | High Similarity | NPC90240 |
0.956 | High Similarity | NPC328914 |
0.9438 | High Similarity | NPC329384 |
0.9195 | High Similarity | NPC190334 |
0.9195 | High Similarity | NPC62927 |
0.8851 | High Similarity | NPC229249 |
0.8261 | Intermediate Similarity | NPC328806 |
0.8211 | Intermediate Similarity | NPC36985 |
0.8211 | Intermediate Similarity | NPC17892 |
0.8125 | Intermediate Similarity | NPC283698 |
0.8125 | Intermediate Similarity | NPC73765 |
0.7895 | Intermediate Similarity | NPC324390 |
0.7812 | Intermediate Similarity | NPC322594 |
0.7812 | Intermediate Similarity | NPC320249 |
0.7474 | Intermediate Similarity | NPC89051 |
0.7474 | Intermediate Similarity | NPC43246 |
0.74 | Intermediate Similarity | NPC317639 |
0.7358 | Intermediate Similarity | NPC329277 |
0.7245 | Intermediate Similarity | NPC315063 |
0.7222 | Intermediate Similarity | NPC155087 |
0.7222 | Intermediate Similarity | NPC149843 |
0.7158 | Intermediate Similarity | NPC106780 |
0.7131 | Intermediate Similarity | NPC318142 |
0.7111 | Intermediate Similarity | NPC315806 |
0.71 | Intermediate Similarity | NPC327344 |
0.6961 | Remote Similarity | NPC318166 |
0.6961 | Remote Similarity | NPC324516 |
0.693 | Remote Similarity | NPC313813 |
0.67 | Remote Similarity | NPC163352 |
0.67 | Remote Similarity | NPC210456 |
0.6667 | Remote Similarity | NPC325723 |
0.6526 | Remote Similarity | NPC329077 |
0.6421 | Remote Similarity | NPC469972 |
0.64 | Remote Similarity | NPC71339 |
0.64 | Remote Similarity | NPC112842 |
0.6341 | Remote Similarity | NPC284651 |
0.6095 | Remote Similarity | NPC171116 |
0.596 | Remote Similarity | NPC325902 |
0.5797 | Remote Similarity | NPC211820 |
0.5797 | Remote Similarity | NPC251233 |
0.5781 | Remote Similarity | NPC315058 |
0.5755 | Remote Similarity | NPC177169 |
0.5714 | Remote Similarity | NPC245534 |
0.5714 | Remote Similarity | NPC232408 |
0.5714 | Remote Similarity | NPC64705 |
0.569 | Remote Similarity | NPC239705 |
0.569 | Remote Similarity | NPC314413 |
0.569 | Remote Similarity | NPC314398 |
0.5683 | Remote Similarity | NPC318590 |
0.5652 | Remote Similarity | NPC186619 |
0.5649 | Remote Similarity | NPC313962 |
0.5643 | Remote Similarity | NPC274384 |
0.5643 | Remote Similarity | NPC89147 |
0.5643 | Remote Similarity | NPC317746 |
0.5641 | Remote Similarity | NPC322449 |
0.5641 | Remote Similarity | NPC189854 |
0.5641 | Remote Similarity | NPC92874 |
0.5641 | Remote Similarity | NPC62845 |
0.5641 | Remote Similarity | NPC166242 |
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules.
●  The left chart: Distribution of similarity level between NPC226769 and all drugs/candidates.
●  The right table: Most similar clinical/approved drugs (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Drug ID | Developmental Stage |
---|---|---|---|
0.956 | High Similarity | NPD1455 | Phase 3 |
0.956 | High Similarity | NPD1454 | Phase 3 |
0.9195 | High Similarity | NPD9602 | Phase 3 |
0.9195 | High Similarity | NPD9603 | Phase 3 |
0.9195 | High Similarity | NPD9604 | Approved |
0.9062 | High Similarity | NPD6946 | Approved |
0.8851 | High Similarity | NPD9601 | Approved |
0.8791 | High Similarity | NPD9585 | Discontinued |
0.8506 | High Similarity | NPD9600 | Approved |
0.8462 | Intermediate Similarity | NPD9553 | Approved |
0.8462 | Intermediate Similarity | NPD9554 | Approved |
0.8462 | Intermediate Similarity | NPD301 | Discontinued |
0.8421 | Intermediate Similarity | NPD514 | Clinical (unspecified phase) |
0.8315 | Intermediate Similarity | NPD9572 | Clinical (unspecified phase) |
0.8286 | Intermediate Similarity | NPD3138 | Phase 3 |
0.828 | Intermediate Similarity | NPD267 | Discontinued |
0.8208 | Intermediate Similarity | NPD3139 | Phase 3 |
0.8202 | Intermediate Similarity | NPD9573 | Phase 2 |
0.8191 | Intermediate Similarity | NPD6943 | Clinical (unspecified phase) |
0.8125 | Intermediate Similarity | NPD9639 | Clinical (unspecified phase) |
0.8021 | Intermediate Similarity | NPD215 | Discontinued |
0.7935 | Intermediate Similarity | NPD9555 | Phase 2 |
0.7865 | Intermediate Similarity | NPD9427 | Approved |
0.7755 | Intermediate Similarity | NPD6948 | Phase 3 |
0.77 | Intermediate Similarity | NPD192 | Phase 2 |
0.7528 | Intermediate Similarity | NPD9407 | Approved |
0.75 | Intermediate Similarity | NPD4743 | Phase 2 |
0.7476 | Intermediate Similarity | NPD7651 | Approved |
0.7474 | Intermediate Similarity | NPD9580 | Clinical (unspecified phase) |
0.7474 | Intermediate Similarity | NPD9581 | Clinical (unspecified phase) |
0.7473 | Intermediate Similarity | NPD9403 | Discontinued |
0.7429 | Intermediate Similarity | NPD3128 | Phase 3 |
0.7407 | Intermediate Similarity | NPD1804 | Phase 2 |
0.7407 | Intermediate Similarity | NPD1805 | Phase 2 |
0.7358 | Intermediate Similarity | NPD1428 | Phase 2 |
0.7358 | Intermediate Similarity | NPD3129 | Phase 3 |
0.7273 | Intermediate Similarity | NPD285 | Discontinued |
0.7204 | Intermediate Similarity | NPD9429 | Discontinued |
0.7191 | Intermediate Similarity | NPD9405 | Approved |
0.7184 | Intermediate Similarity | NPD3121 | Phase 2 |
0.7111 | Intermediate Similarity | NPD9653 | Clinical (unspecified phase) |
0.7018 | Intermediate Similarity | NPD6936 | Clinical (unspecified phase) |
0.7018 | Intermediate Similarity | NPD6935 | Phase 3 |
0.701 | Intermediate Similarity | NPD9557 | Clinical (unspecified phase) |
0.699 | Remote Similarity | NPD762 | Discontinued |
0.6961 | Remote Similarity | NPD1706 | Clinical (unspecified phase) |
0.6916 | Remote Similarity | NPD1061 | Clinical (unspecified phase) |
0.6852 | Remote Similarity | NPD2633 | Phase 1 |
0.6809 | Remote Similarity | NPD9372 | Phase 2 |
0.6759 | Remote Similarity | NPD244 | Clinical (unspecified phase) |
0.67 | Remote Similarity | NPD1760 | Approved |
0.6699 | Remote Similarity | NPD1686 | Approved |
0.6698 | Remote Similarity | NPD5789 | Clinical (unspecified phase) |
0.6667 | Remote Similarity | NPD9565 | Discontinued |
0.6607 | Remote Similarity | NPD6693 | Phase 3 |
0.6598 | Remote Similarity | NPD9556 | Approved |
0.6569 | Remote Similarity | NPD755 | Phase 3 |
0.6538 | Remote Similarity | NPD279 | Clinical (unspecified phase) |
0.6531 | Remote Similarity | NPD9560 | Approved |
0.6531 | Remote Similarity | NPD9561 | Approved |
0.6525 | Remote Similarity | NPD6918 | Phase 1 |
0.6509 | Remote Similarity | NPD2621 | Clinical (unspecified phase) |
0.6481 | Remote Similarity | NPD223 | Clinical (unspecified phase) |
0.6465 | Remote Similarity | NPD9559 | Phase 1 |
0.6465 | Remote Similarity | NPD9546 | Phase 2 |
0.6449 | Remote Similarity | NPD502 | Approved |
0.6429 | Remote Similarity | NPD9558 | Phase 3 |
0.6421 | Remote Similarity | NPD9370 | Approved |
0.64 | Remote Similarity | NPD9533 | Phase 2 |
0.64 | Remote Similarity | NPD280 | Approved |
0.6392 | Remote Similarity | NPD9369 | Clinical (unspecified phase) |
0.6379 | Remote Similarity | NPD7914 | Suspended |
0.6373 | Remote Similarity | NPD241 | Discontinued |
0.6364 | Remote Similarity | NPD2691 | Clinical (unspecified phase) |
0.6275 | Remote Similarity | NPD170 | Approved |
0.6275 | Remote Similarity | NPD9562 | Discovery |
0.6275 | Remote Similarity | NPD240 | Phase 3 |
0.6261 | Remote Similarity | NPD284 | Phase 1 |
0.625 | Remote Similarity | NPD3161 | Clinical (unspecified phase) |
0.6168 | Remote Similarity | NPD501 | Phase 1 |
0.6139 | Remote Similarity | NPD9529 | Phase 1 |
0.6095 | Remote Similarity | NPD841 | Approved |
0.6078 | Remote Similarity | NPD238 | Clinical (unspecified phase) |
0.6078 | Remote Similarity | NPD239 | Phase 2 |
0.604 | Remote Similarity | NPD9534 | Phase 2 |
0.604 | Remote Similarity | NPD9535 | Phase 2 |
0.6 | Remote Similarity | NPD1385 | Discontinued |
0.5981 | Remote Similarity | NPD251 | Approved |
0.5926 | Remote Similarity | NPD7761 | Suspended |
0.5876 | Remote Similarity | NPD9347 | Approved |
0.5876 | Remote Similarity | NPD9346 | Approved |
0.5854 | Remote Similarity | NPD7756 | Clinical (unspecified phase) |
0.5761 | Remote Similarity | NPD9211 | Clinical (unspecified phase) |
0.5714 | Remote Similarity | NPD9654 | Phase 2 |
PubChem CID   | 6131 |
ChEMBL   | CHEMBL307679 |
ZINC   |
Molecular Weight:   | 323.05 |
ALogP:   | -2.3241 |
MLogP:   | 1.13 |
XLogP:   | -2.264 |
# Rotatable Bonds:   | 9 |
Polar Surface Area:   | 185.94 |
# H-Bond Aceptor:   | 11 |
# H-Bond Donor:   | 6 |
# Rings:   | 2 |
# Heavy Atoms:   | 21 |